MindMed, a biomedical company that develops psychedelic-based products for brain disorders, secured $50 million

MindMed, a biomedical company that develops psychedelic-based products for brain disorders, secured $50 million The company says it will help them in areas such as their Phase 2b study of MM-120 (their optimized form of LSD) for the treatment of generalized anxiety disorder later this year. Read the article on Business Wire > Read More from the Global Wellness News ™

Outdoorsy launches $30 million ‘Oasis Fund’ to capitalize on glamping’s explosive growth

Outdoorsy, in tandem with investors and banking partners, launches $30 million ‘Oasis Fund’ to capitalize on glamping’s explosive growth PRNewswire/ — Outdoorsy, the leading outdoor travel marketplace, today announced the launch of the Oasis Fund – a $30 million dollar initiative dedicated… Read More from the Global Wellness News ™

Save Your Cart
Share Your Cart